Pharmicell (005690) - Net Assets

Latest as of September 2025: ₩110.43 Billion KRW ≈ $74.83 Million USD

Based on the latest financial reports, Pharmicell (005690) has net assets worth ₩110.43 Billion KRW (≈ $74.83 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩130.02 Billion ≈ $88.12 Million USD) and total liabilities (₩19.60 Billion ≈ $13.28 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pharmicell (005690) tangible net worth to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩110.43 Billion
% of Total Assets	84.93%
Annual Growth Rate	16.73%
5-Year Change	51.37%
10-Year Change	4.88%
Growth Volatility	203.57

Pharmicell - Net Assets Trend (2010–2024)

This chart illustrates how Pharmicell's net assets have evolved over time, based on quarterly financial data. See how many days can Pharmicell fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Pharmicell (2010–2024)

The table below shows the annual net assets of Pharmicell from 2010 to 2024. For live valuation and market cap data, see 005690 market cap.

Year	Net Assets	Change
2024-12-31	₩86.44 Billion ≈ $58.58 Million	+7.52%
2023-12-31	₩80.40 Billion ≈ $54.48 Million	+4.87%
2022-12-31	₩76.66 Billion ≈ $51.95 Million	+20.03%
2021-12-31	₩63.87 Billion ≈ $43.28 Million	+11.85%
2020-12-31	₩57.11 Billion ≈ $38.70 Million	+10.84%
2019-12-31	₩51.52 Billion ≈ $34.91 Million	+8.48%
2018-12-31	₩47.49 Billion ≈ $32.18 Million	-15.19%
2017-12-31	₩55.99 Billion ≈ $37.95 Million	-40.81%
2016-12-31	₩94.60 Billion ≈ $64.11 Million	+14.77%
2013-12-31	₩82.42 Billion ≈ $55.86 Million	-18.86%
2012-12-31	₩101.58 Billion ≈ $68.84 Million	+22.65%
2011-12-31	₩82.82 Billion ≈ $56.13 Million	+736.15%
2010-12-31	₩9.90 Billion ≈ $6.71 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Pharmicell's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 2555628099000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	₩7.13 Billion	8.25%
Other Components	₩79.31 Billion	91.75%
Total Equity	₩86.44 Billion	100.00%

Pharmicell Competitors by Market Cap

The table below lists competitors of Pharmicell ranked by their market capitalization.

Company	Market Cap
Ta Ann Holdings Bhd KLSE:5012	$579.47 Million
Mutares SE & Co. KGaA XETRA:MUX	$579.48 Million
Sayona Mining Ltd AU:SYA	$579.50 Million
Cheng Uei Precision Industry Co Ltd TW:2392	$579.61 Million
Qingdao Copton Technology Co Ltd SHG:603798	$579.41 Million
Zhejiang Jihua Group Co Ltd SHG:603980	$579.40 Million
Shenzhen King Brother Electronics Technology Co.Ltd. SHE:301041	$579.31 Million
Qurient Co. Ltd KQ:115180	$579.17 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pharmicell's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 80,396,946,740 to 86,439,170,270, a change of 6,042,223,530 (7.5%).
Net income of 6,331,277,000 contributed positively to equity growth.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩6.33 Billion	+7.32%
Other Changes	₩-289.05 Million	-0.33%
Total Change	₩-	7.52%

Book Value vs Market Value Analysis

This analysis compares Pharmicell's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 9.89x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 14.86x to 9.89x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩958.87	₩14250.00	x
2018-12-31	₩792.21	₩14250.00	x
2019-12-31	₩859.43	₩14250.00	x
2020-12-31	₩952.61	₩14250.00	x
2021-12-31	₩1065.48	₩14250.00	x
2022-12-31	₩1277.66	₩14250.00	x
2023-12-31	₩1339.86	₩14250.00	x
2024-12-31	₩1440.56	₩14250.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pharmicell utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 7.32%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 9.76%
• Asset Turnover: 0.65x
• Equity Multiplier: 1.15x
Recent ROE (7.32%) is above the historical average (-17.88%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2010	-119.56%	-164.31%	0.24x	3.00x	₩-12.85 Billion
2011	-21.94%	-176.74%	0.10x	1.22x	₩-26.46 Billion
2012	-17.36%	-158.77%	0.08x	1.34x	₩-27.80 Billion
2013	-31.17%	-76.94%	0.34x	1.21x	₩-33.95 Billion
2016	-0.72%	-2.43%	0.27x	1.08x	₩-10.14 Billion
2017	-70.00%	-155.56%	0.40x	1.14x	₩-44.80 Billion
2018	-26.70%	-44.73%	0.48x	1.24x	₩-17.43 Billion
2019	8.44%	13.38%	0.51x	1.23x	₩-804.78 Million
2020	9.18%	13.88%	0.54x	1.22x	₩-468.72 Million
2021	14.80%	18.24%	0.55x	1.48x	₩3.06 Billion
2022	10.78%	13.73%	0.55x	1.43x	₩595.28 Million
2023	4.45%	6.36%	0.61x	1.15x	₩-4.46 Billion
2024	7.32%	9.76%	0.65x	1.15x	₩-2.31 Billion

Industry Comparison

This section compares Pharmicell's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $440,267,563,751
Average return on equity (ROE) among peers: -6.65%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Pharmicell (005690)	₩110.43 Billion	-119.56%	0.18x	$579.46 Million
ORIENTBIO Inc. (002630)	$44.21 Billion	0.00%	0.54x	$72.49 Million
Green Cross (005250)	$1.85 Trillion	1.30%	0.98x	$342.58 Million
Green Cross Holdings Preference Shares (005257)	$1.88 Trillion	-2.88%	0.99x	$3.26 Million
GeneOne Life Science Inc (011000)	$29.41 Billion	-40.45%	0.68x	$51.80 Million
HLB Co. Ltd (028300)	$18.60 Billion	0.00%	1.06x	$4.45 Billion
Daesung Microbiological Labs. Co. Ltd (036480)	$36.31 Billion	4.18%	0.71x	$16.87 Million
Seoulin Bioscience Co.Ltd (038070)	$45.30 Billion	4.03%	0.46x	$30.03 Million
Hyundai Bioscience Co. Ltd (048410)	$24.60 Billion	2.89%	0.76x	$598.77 Million
iNtRON Biotechnology Inc (048530)	$30.24 Billion	-28.88%	0.51x	$59.56 Million

About Pharmicell

KO:005690 Korea Biotechnology

Market Cap

$579.46 Million

₩855.06 Billion KRW

Market Cap Rank

#11637 Global

#324 in Korea

Share Price

₩14250.00

Change (1 day)

-3.72%

52-Week Range

₩10460.00 - ₩20250.00

All Time High

₩25150.00